Skip to main content
Erschienen in: Brain Tumor Pathology 4/2019

26.07.2019 | Case Report

Anaplastic pleomorphic xanthoastrocytoma associated with an H3G34 mutation: a case report with review of literature

verfasst von: Shoh Sasaki, Ran Tomomasa, Sumihito Nobusawa, Junko Hirato, Tomoko Uchiyama, Eishu Boku, Toshiteru Miyasaka, Takanori Hirose, Chiho Ohbayashi

Erschienen in: Brain Tumor Pathology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Here, we report a rare case of anaplastic pleomorphic xanthoastrocytoma (PXA) associated with an H3G34 mutation. A 12-year-old male presented with loss of appetite, vomiting, headache, and a generalized seizure, and CT revealed a 9.0 cm left frontal lobe mass with some septal walls and a localized high-density area suggestive of hemorrhage or calcification, causing severe midline shift. He emergently underwent subtotal resection and the tumor was morphologically diagnosed as anaplastic PXA. DNA sequencing identified an H3F3A G34R mutation and a TP53 R273H mutation, and immunohistochemically, ATRX nuclear expression was lost. In CNS tumors, H3G34 mutations are essentially detected in glioblastoma (GBM) or central nervous system primitive neuroectodermal tumors. Those tumors most likely comprise a single biological entity (high-grade glioma with H3G34 mutation) because of no significant difference in molecular profiling and prognosis between GBM and PNET morphologies. To our knowledge, our present case is the first one of anaplastic PXA associated with an H3G34 mutation, and whether it biologically corresponds to “high-grade glioma with H3G34 mutation” needs further studies.
Literatur
1.
Zurück zum Zitat Schwartzentruber J, Korshunov A, Liu XY et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384):226–231CrossRef Schwartzentruber J, Korshunov A, Liu XY et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384):226–231CrossRef
2.
Zurück zum Zitat Wu G, Broniscer A, McEachron TA et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251–253CrossRef Wu G, Broniscer A, McEachron TA et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251–253CrossRef
3.
Zurück zum Zitat Sturm D, Witt H, Hovestadt V et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437CrossRef Sturm D, Witt H, Hovestadt V et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437CrossRef
4.
Zurück zum Zitat Gessi M, Gielen GH, Hammes J et al (2013) H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications? J Neurooncol 112(1):67–72CrossRef Gessi M, Gielen GH, Hammes J et al (2013) H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications? J Neurooncol 112(1):67–72CrossRef
5.
Zurück zum Zitat Korshunov A, Capper D, Reuss D et al (2016) Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 131:137–146CrossRef Korshunov A, Capper D, Reuss D et al (2016) Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 131:137–146CrossRef
6.
Zurück zum Zitat Pratt D, Natarajan S, Banda A et al (2018) Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas. Acta Neuropathol 135(2):299–301CrossRef Pratt D, Natarajan S, Banda A et al (2018) Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas. Acta Neuropathol 135(2):299–301CrossRef
7.
Zurück zum Zitat Dias-Santagata D, Lam Q, Vemovsky K et al (2011) BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 6:e17948CrossRef Dias-Santagata D, Lam Q, Vemovsky K et al (2011) BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 6:e17948CrossRef
8.
Zurück zum Zitat Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405CrossRef Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405CrossRef
9.
Zurück zum Zitat Weber RG, Hoischen A, Ehrler M et al (2007) Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytoma. Oncogene 26:1088–1097CrossRef Weber RG, Hoischen A, Ehrler M et al (2007) Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytoma. Oncogene 26:1088–1097CrossRef
10.
Zurück zum Zitat Vaubel RA, Caron AA, Yamada S et al (2018) Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathol 28:172–182CrossRef Vaubel RA, Caron AA, Yamada S et al (2018) Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathol 28:172–182CrossRef
11.
Zurück zum Zitat Zou H, Duan Y, Wei D et al (2019) Molecular features of pleomorphic xanthoastrocytoma. Hum Pathol 86:38–48CrossRef Zou H, Duan Y, Wei D et al (2019) Molecular features of pleomorphic xanthoastrocytoma. Hum Pathol 86:38–48CrossRef
12.
Zurück zum Zitat Phillips JJ, Gong H, Chen K et al (2016) Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p. V600E mutation. Acta Neuropathol 132:757–760CrossRef Phillips JJ, Gong H, Chen K et al (2016) Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p. V600E mutation. Acta Neuropathol 132:757–760CrossRef
13.
Zurück zum Zitat Giannini C, Hebrink D, Scheithauer BW et al (2001) Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma. Neurogenetics 3(3):159–162CrossRef Giannini C, Hebrink D, Scheithauer BW et al (2001) Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma. Neurogenetics 3(3):159–162CrossRef
15.
Zurück zum Zitat Simon JA, Kingston RE (2009) Mechanisms of Polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 10:697–708CrossRef Simon JA, Kingston RE (2009) Mechanisms of Polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 10:697–708CrossRef
16.
Zurück zum Zitat Zhou VW, Goren A, Bernstein BE (2011) Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet 12:7–18CrossRef Zhou VW, Goren A, Bernstein BE (2011) Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet 12:7–18CrossRef
17.
Zurück zum Zitat Wagner EJ, Carpenter PB (2012) Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol 13:115–126CrossRef Wagner EJ, Carpenter PB (2012) Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol 13:115–126CrossRef
18.
Zurück zum Zitat Bjerke L, Mackay A, Nandhabalan M et al (2013) Histone H33 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov 3(5):512–519CrossRef Bjerke L, Mackay A, Nandhabalan M et al (2013) Histone H33 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov 3(5):512–519CrossRef
19.
Zurück zum Zitat Fang J, Huang Y, Mao G et al (2018) Cancer-driving H3G34 V/R/D mutations block H3K36 methylation and H3K36me3-MutSα interaction. PNAS 115(38):9598–9603CrossRef Fang J, Huang Y, Mao G et al (2018) Cancer-driving H3G34 V/R/D mutations block H3K36 methylation and H3K36me3-MutSα interaction. PNAS 115(38):9598–9603CrossRef
20.
Zurück zum Zitat Ida CM, Rodriguez FJ, Burger PC et al (2015) Pleomorphic xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol 25(5):575–586CrossRef Ida CM, Rodriguez FJ, Burger PC et al (2015) Pleomorphic xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol 25(5):575–586CrossRef
21.
Zurück zum Zitat Chang HT, Latorre JG, Hahn S et al (2006) Pediatric cerebellar pleomorphic xanthoastrocytoma with anaplastic features: a case of long-term survival after multimodality therapy. Childs Nerv Syst 22:609–613CrossRef Chang HT, Latorre JG, Hahn S et al (2006) Pediatric cerebellar pleomorphic xanthoastrocytoma with anaplastic features: a case of long-term survival after multimodality therapy. Childs Nerv Syst 22:609–613CrossRef
22.
Zurück zum Zitat Okazaki T, Kageji T, Matsuzaki K et al (2009) Primary anaplastic pleomorphic xanthoastrocytoma with widespread neuroaxis dissemination at diagnosis—a pediatric case report and review of the literature. J Neurooncol 94:431–437CrossRef Okazaki T, Kageji T, Matsuzaki K et al (2009) Primary anaplastic pleomorphic xanthoastrocytoma with widespread neuroaxis dissemination at diagnosis—a pediatric case report and review of the literature. J Neurooncol 94:431–437CrossRef
23.
Zurück zum Zitat Alexiou GA, Moschovi M, Stefanaki K et al (2010) Malignant progression of a pleomorphic xanthoastrocytoma in a child. Neuropediatrics 41:69–71CrossRef Alexiou GA, Moschovi M, Stefanaki K et al (2010) Malignant progression of a pleomorphic xanthoastrocytoma in a child. Neuropediatrics 41:69–71CrossRef
24.
Zurück zum Zitat Marucci G, Morandi L (2011) Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma. J Neurooncol 105:397–400CrossRef Marucci G, Morandi L (2011) Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma. J Neurooncol 105:397–400CrossRef
25.
Zurück zum Zitat Bagriacik EU, Baykaner MK, Yaman M et al (2012) Establishment of a primary pleomorphic xanthoastrocytoma cell line: in vitro responsiveness to some chemotherapeutics. Neurosurgery 70:188–197CrossRef Bagriacik EU, Baykaner MK, Yaman M et al (2012) Establishment of a primary pleomorphic xanthoastrocytoma cell line: in vitro responsiveness to some chemotherapeutics. Neurosurgery 70:188–197CrossRef
26.
Zurück zum Zitat Thompson EM, Landi D, Ashley D et al (2018) Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. J Neurooncol 140:261–268CrossRef Thompson EM, Landi D, Ashley D et al (2018) Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. J Neurooncol 140:261–268CrossRef
Metadaten
Titel
Anaplastic pleomorphic xanthoastrocytoma associated with an H3G34 mutation: a case report with review of literature
verfasst von
Shoh Sasaki
Ran Tomomasa
Sumihito Nobusawa
Junko Hirato
Tomoko Uchiyama
Eishu Boku
Toshiteru Miyasaka
Takanori Hirose
Chiho Ohbayashi
Publikationsdatum
26.07.2019
Verlag
Springer Singapore
Erschienen in
Brain Tumor Pathology / Ausgabe 4/2019
Print ISSN: 1433-7398
Elektronische ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-019-00349-8

Weitere Artikel der Ausgabe 4/2019

Brain Tumor Pathology 4/2019 Zur Ausgabe

Acknowledgment

Reviewers in 2019

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

03.05.2024 Parkinson-Krankheit Nachrichten

Kann eine frühzeitige Stuhltransplantation das Fortschreiten von Parkinson-Symptomen verlangsamen? Die Ergebnisse einer randomisierten Phase-2-Studie scheinen dafür zu sprechen.

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

02.05.2024 Hirnblutung Nachrichten

Erhalten Personen mit einer spontanen Hirnblutung innerhalb von zwei Stunden nach Symptombeginn eine Tranexamsäure-Therapie, kann dies weder die Hämatomexpansion eindämmen noch die Mortalität senken.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.